Innate Pharma (IPHA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Innate Pharma stock (IPHA) is currently trading at $1.26. Innate Pharma PS ratio (Price-to-Sales) is 8.75. Analyst consensus price target for IPHA is $5.75. WallStSmart rates IPHA as Sell.
- IPHA PE ratio analysis and historical PE chart
- IPHA PS ratio (Price-to-Sales) history and trend
- IPHA intrinsic value — DCF, Graham Number, EPV models
- IPHA stock price prediction 2025 2026 2027 2028 2029 2030
- IPHA fair value vs current price
- IPHA insider transactions and insider buying
- Is IPHA undervalued or overvalued?
- Innate Pharma financial analysis — revenue, earnings, cash flow
- IPHA Piotroski F-Score and Altman Z-Score
- IPHA analyst price target and Smart Rating
Innate Pharma
📊 No data available
Try selecting a different time range
Smart Analysis
Innate Pharma (IPHA) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Innate Pharma (IPHA) Key Strengths (0)
Supporting Valuation Data
Innate Pharma (IPHA) Areas to Watch (8)
Company is destroying shareholder value
Losing money on operations
Revenue declining -60.60%, a shrinking business
Earnings declining -74.70%, profits shrinking
Very expensive at 8.8x annual revenue
Very expensive at 18.7x book value
Very low institutional interest at 0.37%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Innate Pharma (IPHA) Detailed Analysis Report
Overall Assessment
This company scores 9/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 0 register as strengths (avg 0/10) while 8 fall into concern territory (avg 1.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (8.75), Price/Book (18.66) suggest expensive pricing. Growth concerns include Revenue Growth at -60.60%, EPS Growth at -74.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -271.40%, Operating Margin at -523.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -271.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -60.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IPHA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IPHA's Price-to-Sales ratio of 8.75x trades 16% below its historical average of 10.38x (55th percentile). The current valuation is 75% below its historical high of 35.29x set in Dec 2021, and 215% above its historical low of 2.78x in Nov 2024. Over the past 12 months, the PS ratio has compressed from ~14.7x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Innate Pharma (IPHA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Innate Pharma operates as a stable business with moderate growth and solid fundamentals. Revenue reached 13M with 61% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 162% of revenue (21M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 61% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -31M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Innate Pharma.
Bottom Line
Innate Pharma offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:21:55 AM
About Innate Pharma(IPHA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France and internationally. The company is headquartered in Marseille, France.